点亮环球疫情的新希望:君实生物(01877.HK)全力推进新冠中和抗体,抢滩疫苗市场
4月27日,国务院新闻办公室举行的会议上,多位专家介绍了新冠肺炎疫情相关科学研究情况,指出现阶段血浆等治疗手段在中国取得了比较好的疗效。其中,来自中国科学院微生物研究所的研究员严景华,提出另一种中和抗体疗法。中和抗体比血浆更容易生产、靶标也更明确。从目前的情况来看,动物实验结果非常好,预防和保护都很好,毒理上看也非常安全。在疫苗出来之前,有机会成为很好的一个治疗方法。
中和抗体(Neutralizing Antibody)是一种可通过中和或抑制病原体(例如病毒)的生物学活性来保护细胞免受侵害的治疗性抗体。抗体疗法具备多种优势,能够同时用于治疗和预防;由于人源化抗体对病原体具有高度的特异性,在安全性上有所保障;与痊愈病人血清相比,抗体可以通过工程化实现药物量产,从而保证临床大量应用。
早在三月下旬,君实生物(01877.HK)已宣布与中国科学院微生物研究所签订了项目合作协议,拟共同开发生产新型冠状病毒中和抗体,提供治疗COVID-19的创新型药物。君实生物的首席运营官冯辉在3月31日的一场投资者交流会上透露,已获得两个具有高亲和力的新冠病毒中和抗体,具备单独临床或联合临床的潜力。目前正在国内科研机构进行更多体外研究和安全性评价,并与各国监管机构协商开展试验。同时,为了保证下一步大规模生产的顺利实施,厂房将通过2000升反应器进行生产。君实生物副总经理姚盛则表示,新冠中和抗体的研究目前在公司的整体布局中处于优先地位,保证中和抗体能尽快进入临床。
作为目前唯一由中国研究机构和上市企业合作开展,并进入动物实验环节的中和抗体,这项应用已进入关键环节,有望实现产业化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.